<DOC>
	<DOCNO>NCT00451646</DOCNO>
	<brief_summary>The aim study evaluate safety tolerance SMOFlipid 20 % comparison standard lipid emulsion Intralipid 20 % patient require long-term parenteral nutrition . The safety tolerance evaluate biochemistry , hematology coagulation variable , vital sign adverse event . Further objectives evaluate influence SMOFlipid 20 % inflammation process , efficacy anti-oxidative property vitamin E supplement SMOFlipid 20 % , fatty acid pattern red blood cell serum .</brief_summary>
	<brief_title>Study Comparing Safety Tolerance SMOFlipid 20 % Long-term Treatment With Parenteral Nutrition</brief_title>
	<detailed_description />
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>In outpatient need parenteral nutrition due inability sustain adequate oral/enteral food intake least 4 week Written consent subject Known hypersensitivity fish , egg , soy , peanutprotein active substance excipients Known type IV hyperlipidemia , disturbance lipid metabolism hypertriglyceridemia Severe liver insufficiency Severe blood coagulation disorder Subjects chronic stable renal insufficiency define Screatinine value &gt; 25 mg/l ( 200 Âµmol/l ) receive dialysis/hemofiltration therapy General contraindication infusion therapy : acute pulmonary oedema , hyperhydration Unstable condition Unstable angina pectoris Acute shock Chemotherapy within 4 week start trial Chemotherapy trial Subjects trial treatment appropriate Female patient must surgically sterile ; postmenopausal least two year ; childbearing potential must negative serum pregnancy test must agree maintain adequate birth control practice study . Participation another clinical study investigational drug investigational medical device within one month prior start study study Prior inclusion present study Any feature opinion investigator preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>